- Trials with a EudraCT protocol (89)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
89 result(s) found for: Bulbar palsy.
Displaying page 1 of 5.
EudraCT Number: 2016-002382-62 | Sponsor Protocol Number: RNS60-ALS | Start Date*: 2017-01-13 | |||||||||||||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||||||||||||
Full Title: The effects of RNS60 on ALS biomarkers | |||||||||||||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003875-32 | Sponsor Protocol Number: P288ALS | Start Date*: 2021-12-22 | |||||||||||
Sponsor Name:InFlectis BioScience | |||||||||||||
Full Title: A double-blind, placebo-controlled, exploratory randomised clinical trial to assess the safety and efficacy of IFB-088 plus riluzole 100 mg vs placebo plus riluzole 100 mg in patients with bulbar-o... | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (bulbar-onset) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004459-21 | Sponsor Protocol Number: Co-ALS | Start Date*: 2018-09-11 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA | ||||||||||||||||||
Full Title: Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial | ||||||||||||||||||
Medical condition: Definite or probable amyotrophic lateral sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-005103-27 | Sponsor Protocol Number: BETASBMA | Start Date*: 2021-11-18 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA | |||||||||||||
Full Title: A PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CLENBUTEROL IN PATIENTS WITH SPINAL AND BULBAR MUSCULAR ATROPHY (SBMA) | |||||||||||||
Medical condition: Motor neuron disease characterized by atrophy and muscle weakness in the spinal and bulbar region | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005810-31 | Sponsor Protocol Number: MD1003CT2015-02-ALS | Start Date*: 2016-06-03 | |||||||||||
Sponsor Name:MEDDAY PHARMACEUTICALS | |||||||||||||
Full Title: Effect of MD1003 in amyotrophic lateral sclerosis: a randomized, double blind placebo controlled study | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004165-17 | Sponsor Protocol Number: 2289/2007 | Start Date*: 2007-09-25 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA PISANA | |||||||||||||
Full Title: Efficacy assessment of ceftriaxone therapy in patients with amyotrophic lateral sclerosis. | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020010-28 | Sponsor Protocol Number: EDTA | Start Date*: 2010-09-22 | |||||||||||
Sponsor Name:Dr.ssa Marina Aiello-Universit� degli studi di Parma | |||||||||||||
Full Title: EVALUATION OF RESPIRATORY MUSCLES` FUNCTION IN PATIENTS AFFECTED BY ALS WITH HEAVY METAL POISONING | |||||||||||||
Medical condition: PATIENTS AFFECTED BY ALS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010060-41 | Sponsor Protocol Number: 2707/2009 | Start Date*: 2009-02-24 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA PISANA | |||||||||||||
Full Title: Evaluation of efficacy of lithium salts therapy in patients with Amyotrophic Lateral Sclerosis. | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003248-75 | Sponsor Protocol Number: STEMALS 01 | Start Date*: 2005-08-31 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: PILOT STUDY ON SAFETY AND TOLERABILITY OF REPEATED MOBILIZATION PROCEDURES OF OSTEO-MEDULLARY DERIVED CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS | |||||||||||||
Medical condition: SLOWING OF ALS PROGRESSION | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005152-40 | Sponsor Protocol Number: ALALS | Start Date*: 2006-04-19 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO | |||||||||||||
Full Title: MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS | |||||||||||||
Medical condition: ALS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002117-39 | Sponsor Protocol Number: MEDALS | Start Date*: 2008-01-31 | |||||||||||
Sponsor Name:Jorge Matias-Guiu Guia | |||||||||||||
Full Title: MEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICA MEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS . | |||||||||||||
Medical condition: Esclerosis Lateral Amiotrofica Amyotrophic lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002379-16 | Sponsor Protocol Number: 2007-002379-16 | Start Date*: 2007-05-29 | |||||||||||
Sponsor Name:I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX | |||||||||||||
Full Title: MULTICENTER TRIAL (SINGLE BLIND)VS ON THE EFFICACY OF LITHIUM SALTS +RILUZOLE VS PLACEBO+RILUZOLE IN PATIENTS AFFECTED BY AMYOTROPHIC LATERAL SCLEROSIS | |||||||||||||
Medical condition: Patients affected by amyotrophic lateral sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006511-29 | Sponsor Protocol Number: PTC857-CNS-001-ALS | Start Date*: 2022-08-26 | |||||||||||
Sponsor Name:PTC Therapeutics, Inc. | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL ... | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Trial now transitioned) NL (Ongoing) NO (Trial now transitioned) SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007320-25 | Sponsor Protocol Number: TRO19622 CL E Q 1015-1 | Start Date*: 2009-06-24 | |||||||||||
Sponsor Name:TROPHOS SA | |||||||||||||
Full Title: Phase II/III, multicenter, randomized, parallel group,double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with r... | |||||||||||||
Medical condition: ALS is a fatal neuromuscular disorder causing progressive loss of nervous control of voluntary muscles because of destruction of motor neurons in the brain and spinal cord.Riluzole is the only appr... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004158-23 | Sponsor Protocol Number: 3303 | Start Date*: 2005-04-15 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON THE USE OF ACETYL-L-CARNITINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000376-38 | Sponsor Protocol Number: MT-1186-A03 | Start Date*: 2021-03-22 | |||||||||||
Sponsor Name:Mitsubishi Tanabe Pharma Development America, Inc. | |||||||||||||
Full Title: A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003900-42 | Sponsor Protocol Number: MT-1186-A04 | Start Date*: 2022-07-15 | |||||||||||
Sponsor Name:Mitsubishi Tanabe Pharma America, Inc. (MTPA) | |||||||||||||
Full Title: A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following S... | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004040-29 | Sponsor Protocol Number: CY5031 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Cytokinetics Inc | |||||||||||||
Full Title: A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS). | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IE (Prematurely Ended) FR (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004590-51 | Sponsor Protocol Number: 233AS303 | Start Date*: 2021-09-15 | |||||||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||||||||||||
Full Title: A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed... | |||||||||||||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) BE (Completed) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005347-14 | Sponsor Protocol Number: H2020/PHRC-N/2014/GB-01 | Start Date*: 2016-08-25 | |||||||||||
Sponsor Name:CHU DE NIMES | |||||||||||||
Full Title: Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, pla... | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
